Mucosal immunization with PLGA-microencapsulated DNA primes a SIV-specific CTL response revealed by boosting with cognate recombinant modified vaccinia virus Ankara.

Mucosal immunization with PLGA-microencapsulated DNA primes a SIV-specific CTL response revealed by boosting with cognate recombinant modified vaccinia virus Ankara.

Systemically administered DNA encoding a recombinant human immunodeficiency virus (HIV) derived immunogen effectively primes a cytotoxic T lymphocyte (CTL) response in macaques. In this further pilot study we have evaluated mucosal delivery of DNA as an alternative priming strategy. Plasmid DNA, pTH...

Podrobná bibliografie
Hlavní autoři:	Sharpe, S, Hanke, T, Tinsley-Bown, A, Dennis, M, Dowall, S, McMichael, A, Cranage, M
Médium:	Journal article
Jazyk:	English
Vydáno:	2003

Podobné jednotky

Induction of simian immunodeficiency virus (SIV)-specific CTL in rhesus macaques by vaccination with modified vaccinia virus Ankara expressing SIV transgenes: influence of pre-existing anti-vector immunity.
Autor: Sharpe, S, a další
Vydáno: (2001)

Effective induction of simian immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multiepitope gene and DNA prime-modified vaccinia virus Ankara boost vaccination regimen.
Autor: Hanke, T, a další
Vydáno: (1999)

Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen.
Autor: Allen, T, a další
Vydáno: (2000)

Immunodominance of poxviral-specific CTL in a human trial of recombinant-modified vaccinia Ankara.
Autor: Smith, C, a další
Vydáno: (2005)

Immunogenicities of intravenous and intramuscular administrations of modified vaccinia virus Ankara-based multi-CTL epitope vaccine for human immunodeficiency virus type 1 in mice.
Autor: Hanke, T, a další
Vydáno: (1998)

Protection against highly pathogenic SIV by BCG-SIV recombinant priming and attenuated replicating vaccinia-SIV recombinant boosting
Autor: Zhang X, a další
Vydáno: (2012-09-01)

SIV INFECTION OF CYNOMOLGUS MACAQUES - ANALYSIS OF CTL DURING THE EARLY PHASE OF INFECTION, AND IMMUNIZATION PROTECTION EXPERIMENT USING RECOMBINANT SIV PROTEINS AS SOLID MATRIX-ANTIBODY-ANTIGEN (SMAA)
Autor: Hanke, T, a další
Vydáno: (1995)

Recombinant modified vaccinia Ankara primes functionally activated CTL specific for a melanoma tumor antigen epitope in melanoma patients with a high risk of disease recurrence.
Autor: Smith, C, a další
Vydáno: (2005)

Pre-clinical development of a multi-CTL epitope-based DNA prime MVA boost vaccine for AIDS.
Autor: Hanke, T, a další
Vydáno: (1999)

HIV and SIV CTL escape: implications for vaccine design.
Autor: Goulder, P, a další
Vydáno: (2004)

CTL escape and viral fitness in HIV/SIV infection
Autor: Sayuri eSeki, a další
Vydáno: (2012-01-01)

Clinical experience with plasmid DNA- and modified vaccinia virus Ankara-vectored human immunodeficiency virus type 1 clade A vaccine focusing on T-cell induction.
Autor: Hanke, T, a další
Vydáno: (2007)

Microencapsulation of gentamicin into PLGA-chitosan matrices
Autor: Abdullah Hazim, Anas, a další
Vydáno: (2011)

Replication-deficient recombinant adenoviruses expressing the human immunodeficiency virus Env antigen can induce both humoral and CTL immune responses in mice.
Autor: Bruce, C, a další
Vydáno: (1999)

Effects of cytotoxic T lymphocytes (CTL) directed against a single simian immunodeficiency virus (SIV) Gag CTL epitope on the course of SIVmac239 infection.
Autor: Allen, T, a další
Vydáno: (2002)

Lack of toxicity and persistence in the mouse associated with administration of candidate DNA- and modified vaccinia virus Ankara (MVA)-based HIV vaccines for Kenya.
Autor: Hanke, T, a další
Vydáno: (2002)

Recombinant modified vaccinia virus Ankara efficiently restimulates human cytotoxic T lymphocytes in vitro.
Autor: Dorrell, L, a další
Vydáno: (2000)

Microencapsulation of Cassia Alata extract into biodegradable PLGA
Autor: Alfatama, Mulham, a další
Vydáno: (2011)

Clinical development of Modified Vaccinia virus Ankara vaccines.
Autor: Gilbert, S
Vydáno: (2013)

Clinical development of Modified Vaccinia virus Ankara vaccines
Autor: Gilbert, S
Vydáno: (2013)

Estimating Costs and Benefits of CTL Escape Mutations in SIV/HIV Infection.
Autor: Vitaly V Ganusov, a další
Vydáno: (2006-03-01)

Cardiac Safety in Clinical Trials with Preventive HIV Vaccine Candidates Based on Modified Vaccinia Ankara (MVA)
Autor: Schmidt, C, a další
Vydáno: (2008)

Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: effects of dosage and route on safety and immunogenicity.
Autor: Peters, B, a další
Vydáno: (2007)

Prevention of SIV rectal transmission and priming of T cell responses in macaques after local pre-exposure application of tenofovir gel.
Autor: Martin Cranage, a další
Vydáno: (2008-08-01)

Therapeutic vaccination against hepatitis B virus using heterolgous prime boost strategy with DNA and modified vaccinia virus ankara vectors
Autor: McConkey, S, a další
Vydáno: (2003)

Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans.
Autor: McShane, H, a další
Vydáno: (2004)

Sequential Immunization with gp140 Boosts Immune Responses Primed by Modified Vaccinia Ankara or DNA in HIV-Uninfected South African Participants.
Autor: Gavin Churchyard, a další
Vydáno: (2016-01-01)

Modified vaccinia Ankara expressing HIVA antigen stimulates HIV-1-specific CD8 T cells in ELISpot assays of HIV-1 exposed infants.
Autor: Slyker, J, a další
Vydáno: (2005)

Increased detection of proliferating, polyfunctional, HIV-1-specific T cells in DNA-modified vaccinia virus Ankara-vaccinated human volunteers by cultured IFN-gamma ELISPOT assay.
Autor: Winstone, N, a další
Vydáno: (2009)

Safety and immunogenicity of novel recombinant BCG and modified vaccinia virus Ankara vaccines in neonate rhesus macaques.
Autor: Rosario, M, a další
Vydáno: (2010)

Improved Host Range Selection for Recombinant Modified Vaccinia Virus Ankara
Autor: Caroline Staib, a další
Vydáno: (2003-04-01)

Development of Modified Vaccinia Virus Ankara-Based Vaccines: Advantages and Applications
Autor: Olga Vladimirovna Orlova, a další
Vydáno: (2022-09-01)

Elements in the Development of a Production Process for Modified Vaccinia Virus Ankara
Autor: Volker Sandig, a další
Vydáno: (2013-11-01)

Biodistribution and persistence of an MVA-vectored candidate HIV vaccine in SIV-infected rhesus macaques and SCID mice.
Autor: Hanke, T, a další
Vydáno: (2005)

Erratum: Clinical experience with plasmid DNA- and modified vaccinia virus Ankara-vectored human immunodeficiency virus type 1 clade A vaccine focusing on T-cell induction (Journal of General Virology (2007) vol. 88 ( 1) (1-12))
Autor: Hanke, T, a další
Vydáno: (2008)

Prime-boost immunization with adenoviral and modified vaccinia virus Ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responses.
Autor: Reyes-Sandoval, A, a další
Vydáno: (2010)

Preferential targeting of conserved Gag regions after vaccination with a heterologous DNA prime Modified Vaccinia Ankara boost HIV vaccine regime
Autor: Bauer A, a další
Vydáno: (2012-09-01)

Vaccination with a modified vaccinia virus Ankara (MVA)-vectored HIV-1 immunogen induces modest vector-specific T cell responses in human subjects.
Autor: Howles, S, a další
Vydáno: (2010)

Safety and tolerability of recombinant modified vaccinia virus Ankara expressing an HIV-1 gag/multiepitope immunogen (MVA.HIVA) in HIV-1-infected persons receiving combination antiretroviral therapy.
Autor: Dorrell, L, a další
Vydáno: (2007)

Transient Host Range Selection for Genetic Engineering of Modified Vaccinia Virus Ankara
Autor: C. Staib, a další
Vydáno: (2000-06-01)